Effects of orelabrutinib on antibody mediated platelet destruction in ITP
B cells were collected from the peripheral blood of four treatment naive newly diagnosed ITP patients. They were treated with orelabrutinib or DMSO as a control for 1 hour before IgM activation. Cells were collected 24 hours later and dissolved in TRIzol reagent. Sequencing was performed using Illumina NovaSeq 6000.